AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ALKS · NASDAQ · Drug Manufacturers - Specialty & Generic

Alkermes (ALKS)

Develops and sells neuroscience medicines spanning addiction, psychiatry and sleep disorders.

$43.71

vs last close−0.47 (−1.06%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	381	377	350	399	378	430	307	391	394	385	393	496
Cost of revenue	61	70	59	61	63	62	49	49	52	46	62	98
Gross profit	319	307	292	338	315	368	257	341	343	338	331	398
	230	129	248	228	210	205	244	248	254	280	380	380
Research & development	65	−21	68	60	60	57	72	77	82	93	103	113
	156	141	180	168	150	147	172	171	172	190	265	218
Selling & marketing	115	116	126	120	102	99	123	121	116	90	156	154
General & administrative	42	24	54	48	48	48	49	50	56	101	109	63
Other expenses	9	9	1	0	0	2	0	0	0	−3	12	49
Operating income	89	179	43	110	105	163	14	93	89	58	−48	18
	4	4	4	7	5	7	12	12	12	2	−14	−20
Interest income	9	10	9	11	11	11	10	11	12	12	9	5
Interest expense	6	6	6	6	6	5	0	0	0	12	21	26
Other non-operating income	−10	−10	−10	−13	−11	−12	−12	−12	−12	−15	−7	−6
Income before tax	93	182	47	117	110	170	25	105	101	60	−62	−2
Income tax expense	1	−94	8	22	17	24	3	18	18	11	5	−2
Net income from continuing operations	92	276	39	95	93	146	22	87	83	49	−66	1
Discontinued operations	−44	0	−2	−3	0	1	0	0	0	0	0	0
Other adjustments	0	−163	0	0	0	0	0	0	0	0	0	0
Net income	48	113	37	91	92	147	22	87	83	49	−66	1
EPS, basic	$0.29	$0.68	$0.22	$0.54	$0.57	$0.90	$0.14	$0.53	$0.50	$0.30	−$0.40	$0.00
EPS, diluted	$0.28	$0.66	$0.21	$0.53	$0.55	$0.88	$0.13	$0.52	$0.49	$0.29	−$0.40	$0.00
Weighted average shares, basic	167	167	168	168	163	162	163	165	165	165	166	167
Weighted average shares, diluted	172	170	173	171	167	167	169	168	169	169	166	167
EBITDA	117	207	61	129	123	181	33	113	109	77	−22	54
Depreciation & amortization	19	19	8	7	7	7	7	8	8	4	19	30
EBIT	99	188	53	123	116	175	25	105	101	73	−41	24